MCID: AST007
MIFTS: 52

Astrocytoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Astrocytoma

MalaCards integrated aliases for Astrocytoma:

Name: Astrocytoma 12 77 30 56 6 45 15 17 74
Cerebral Astrocytoma 12 74
Astrocytoma, No Icd-O Subtype 12
Astrocytoma of Cerebrum 12
Astrocytoma of Brain 12
Astrocytic Tumor 12
Astroglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3069
MeSH 45 D001254
SNOMED-CT 69 38713004

Summaries for Astrocytoma

Disease Ontology : 12 A malignant glioma that is has material basis in astrocyte cells, a type of star-shaped glial cell, located in the brain and spinal cord.

MalaCards based summary : Astrocytoma, also known as cerebral astrocytoma, is related to pilomyxoid astrocytoma and glioblastoma. An important gene associated with Astrocytoma is IDH1 (Isocitrate Dehydrogenase (NADP(+)) 1, Cytosolic). The drugs Temozolomide and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and t cells.

Wikipedia : 77 Astrocytomas are a type of cancer of the brain. They originate in a particular kind of glial cells,... more...

Related Diseases for Astrocytoma

Diseases in the Astrocytoma family:

Juvenile Astrocytoma

Diseases related to Astrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 392)
# Related Disease Score Top Affiliating Genes
1 pilomyxoid astrocytoma 33.8 FGFR1 H19
2 glioblastoma 32.1 FGFR1 H19 HOTAIR HOXA-AS3 IDH1 MIR21
3 glioma 31.7 CASC2 FGFR1 H19 HOTAIR IDH1 MIR21
4 medulloblastoma 31.2 FGFR1 H19 HOTAIR IDH1
5 malignant glioma 31.0 CASC2 CCDC26 HOTAIR HOXA-AS3
6 breast cancer 30.8 CASC2 CCDC26 FGFR1 H19 HOTAIR IDH1
7 leukemia, acute myeloid 30.8 CCDC26 HOTAIR IDH1 MIR21 PTPN11
8 myeloma, multiple 30.7 H19 HOTAIR IDH1 PTPN11 TP73-AS1
9 renal cell carcinoma, nonpapillary 30.6 CASC2 H19 HOTAIR LBX2-AS1
10 osteogenic sarcoma 30.5 CASC2 H19 HOTAIR SNHG1
11 prostate cancer 30.4 CASC2 FGFR1 H19 HOTAIR MIR106A MIR21
12 pilocytic astrocytoma 12.6
13 fibrillary astrocytoma 12.6
14 grade iii astrocytoma 12.6
15 subependymal giant cell astrocytoma 12.5
16 melanoma-astrocytoma syndrome 12.5
17 spinal cord astrocytoma 12.3
18 cerebellar astrocytoma 12.2
19 gemistocytic astrocytoma 12.2
20 protoplasmic astrocytoma 12.2
21 juvenile pilocytic astrocytoma 12.2
22 pilocytic astrocytoma of cerebellum 12.2
23 childhood pilocytic astrocytoma 12.2
24 juvenile astrocytoma 12.2
25 optic nerve astrocytoma 12.2
26 diencephalic astrocytomas 12.2
27 desmoplastic infantile astrocytoma 12.1
28 childhood cerebral astrocytoma 12.1
29 desmoplastic infantile astrocytoma/ganglioglioma 12.1
30 glioma susceptibility 1 12.0
31 childhood optic tract astrocytoma 12.0
32 pineal gland astrocytoma 12.0
33 adult brainstem astrocytoma 12.0
34 childhood brainstem astrocytoma 12.0
35 mixed astrocytoma-ependymoma-oligodendroglioma 12.0
36 mixed astrocytoma-ependymoma 12.0
37 mixed oligodendroglioma-astrocytoma 12.0
38 cauda equina intradural extramedullary astrocytoma 11.9
39 cerebellar astrocytoma, childhood 11.9
40 oligoastrocytoma 11.9
41 tuberous sclerosis 11.5
42 glioblastoma multiforme 11.5
43 brain stem astrocytic neoplasm 11.5
44 diencephalic syndrome 11.4
45 subependymoma 11.4
46 li-fraumeni syndrome 11.4
47 li-fraumeni syndrome 2 11.4
48 pleomorphic xanthoastrocytoma 11.3
49 adult infiltrating astrocytic neoplasm 11.1
50 glioma susceptibility 2 11.0

Graphical network of the top 20 diseases related to Astrocytoma:



Diseases related to Astrocytoma

Symptoms & Phenotypes for Astrocytoma

Drugs & Therapeutics for Astrocytoma

Drugs for Astrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 653)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 85622-93-1 5394
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 53123-88-9 46835353 5284616 6436030
4
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 159351-69-6 70789204 6442177
5
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1401-55-4
6
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
7 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
8 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
9 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
10 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
11 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
12 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
13 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
14 Antifungal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
15
Etoposide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 33419-42-0 36462
16
Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 52-24-4 5453
17
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
18
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 50-18-0, 6055-19-2 2907
19
Carboplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
20
Carmustine Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 154-93-8 2578
21
Tranexamic Acid Approved Phase 3 1197-18-8 5526
22
Lomustine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 13010-47-4 3950
23
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
24
Methotrexate Approved Phase 3,Phase 2,Not Applicable 1959-05-2, 59-05-2 126941
25
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
26
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
27
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
28
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
29
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
30
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
31
Trioxsalen Approved Phase 3,Phase 2,Phase 1 3902-71-4 5585
32
Procarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 671-16-9 4915
33
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
34
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
35
Angiotensin II Approved, Investigational Phase 3,Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
36
Losartan Approved Phase 3,Phase 2 114798-26-4 3961
37
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1 100286-90-6, 97682-44-5 60838
38
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
39
Bevacizumab Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 216974-75-3
40
Sunitinib Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 557795-19-4, 341031-54-7 5329102
41
Ethanol Approved Phase 2, Phase 3,Phase 1,Early Phase 1 64-17-5 702
42
Aminolevulinic acid Approved Phase 3,Phase 1,Phase 2,Not Applicable 106-60-5 137
43
Hydroxychloroquine Approved Phase 2, Phase 3,Phase 1 118-42-3 3652
44
Thioguanine Approved Phase 3,Phase 2 154-42-7 2723601
45
Cobalt Approved, Experimental Phase 3 7440-48-4 104729
46
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
47
Isotretinoin Approved Phase 3,Phase 2,Phase 1 4759-48-2 5282379 5538
48
Vorinostat Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 149647-78-9 5311
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
50
Granisetron Approved, Investigational Phase 3 109889-09-0 3510

Interventional clinical trials:

(show top 50) (show all 1537)
# Name Status NCT ID Phase Drugs
1 Supra-early Post-Surgery Chemotherapy in the Treatment on GBM Patients Unknown status NCT02520635 Phase 4 supra-early TEMODAL® chemotherapy;standard TEMODAL® chemotherapy
2 Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) Completed NCT00686725 Phase 4 Temozolomide
3 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
4 Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301 Active, not recruiting NCT02338609 Phase 4 Everolimus;Envirolimus drug class as prescribed by Physician
5 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
6 Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
8 Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Unknown status NCT01730209 Phase 2, Phase 3 Everolimus;Placebo
9 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
10 Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
11 Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
12 Carboplatin Plus Vincristine in Treating Children and Adolescents With Low Grade Glioma Unknown status NCT00003015 Phase 3 carboplatin;vincristine sulfate
13 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
14 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
15 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
16 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma Unknown status NCT01805453 Phase 3 Losartan;Placebo
17 Metronomic Temozolamide in Patients With Recurrent Glioblastoma Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
18 Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Completed NCT00789828 Phase 3 Everolimus;Placebo
19 Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644) Completed NCT00335075 Phase 3 Temozolomide;Semustine
20 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Completed NCT00004259 Phase 3 BCNU 80mg/m2;TMZ 200mg/m2;CCNU;BCNU 150mg/m2;BCNU 200mg/m2;TMZ 150mg/m2 six 6-week cycles;TMZ 150mg/m2 six 8-week cycles
21 Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly Completed NCT01502241 Phase 3 Temozolomide
22 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
23 Combination Chemotherapy in Treating Children With Progressive Brain Tumors Completed NCT00002944 Phase 3 carboplatin;lomustine;procarbazine hydrochloride;thioguanine;vincristine sulfate
24 Radiation Therapy in Treating Patients With Brain Cancer Completed NCT00002620 Phase 3 carmustine;chemotherapy;mitolactol
25 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
26 Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
27 Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
28 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3 Temozolomide
29 High Light and Low Light Dose PDT in Glioma Completed NCT00118222 Phase 3 porfimer sodium
30 High-Dose Chemotherapy Plus Autologous Stem Cell Transplantation Compared With Intermediate-Dose Chemotherapy Plus Autologous Stem Cell Transplantation With or Without Isotretinoin in Treating Young Patients With Recurrent High-Grade Gliomas Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
31 Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma Completed NCT00003375 Phase 2, Phase 3 lomustine;procarbazine hydrochloride;vincristine sulfate
32 Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
33 Radiation Therapy or Temozolomide in Treating Patients With Gliomas Completed NCT00182819 Phase 3 temozolomide
34 Standard Radiation Therapy With or Without Stereotactic Radiation Therapy in Treating Patients With Glioma Completed NCT00003916 Phase 3
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
36 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
37 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
38 An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies Completed NCT00226655 Phase 3 hCRF [XERECEPT (corticorelin acetate injection)]
39 XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors Completed NCT00088166 Phase 3 hCRF;placebo hCRF
40 Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Completed NCT00790400 Phase 3 Everolimus (RAD001);Everolimus Placebo
41 A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE) Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
42 Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
43 Short Course vs. Standard Course Radiotherapy in Elderly and/or Frail Patients With Glioblastoma Multiforme Completed NCT01450449 Phase 3
44 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
45 Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
46 A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
47 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
48 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
49 Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme Completed NCT00820963 Phase 3 temozolomide
50 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)

Search NIH Clinical Center for Astrocytoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: astrocytoma

Genetic Tests for Astrocytoma

Genetic tests related to Astrocytoma:

# Genetic test Affiliating Genes
1 Astrocytoma 30

Anatomical Context for Astrocytoma

MalaCards organs/tissues related to Astrocytoma:

42
Brain, Spinal Cord, T Cells, Bone, Testes, Endothelial, Prostate

Publications for Astrocytoma

Articles related to Astrocytoma:

(show top 50) (show all 3088)
# Title Authors Year
1
Adult Pilomyxoid Astrocytoma with Hemorrhage in an Atypical Location. ( 30937060 )
2019
2
Prognostic Significance of Anatomic Origin and Evaluation of Survival Statistics of Astrocytoma Patients-a Tertiary Experience. ( 30948873 )
2019
3
Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis. ( 30953904 )
2019
4
A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery. ( 30972543 )
2019
5
Microsurgical management of fourth ventricle astrocytoma via the median suboccipital keyhole approach: A review of 12 cases. ( 30974274 )
2019
6
Correction: Inhibition of Furin-mediated Processing Results in Suppression of Astrocytoma Cell Growth and Invasiveness. ( 30988098 )
2019
7
Usefulness of [11C] Methionine PET in the Differentiation of Tumefactive Multiple Sclerosis from High Grade Astrocytoma. ( 30996153 )
2019
8
Twenty-three years follow-up after low-dose Gamma Knife surgery of a brainstem juvenile pilocytic astrocytoma: a case report and review of the literature. ( 30997566 )
2019
9
Angiocentric astrocytoma in a cat. ( 31018782 )
2019
10
Hypertrophic olivary degeneration in a 16-year-old girl after subtotal surgery of a brainstem pilocytic astrocytoma - a case report. ( 31019597 )
2019
11
Significance of Amphiregulin (AREG) for the Outcome of Low and High Grade Astrocytoma Patients. ( 31031857 )
2019
12
Comparison of conventional, diffusion, and perfusion MRI between infratentorial ganglioglioma and pilocytic astrocytoma. ( 31032625 )
2019
13
Radiation-induced anaplastic astrocytoma following treatment of medulloblastoma. ( 31038191 )
2019
14
Bevacizumab Use in Refractory Adult Pilocytic Astrocytoma: A Single-Center Case Series. ( 31045718 )
2019
15
Multifocal Infra-Tentorial Pilocytic Astrocytoma in an Adult Patient: A Case Report. ( 31082554 )
2019
16
Slowdown intracranial glioma progression by optical hyperthermia therapy: study on a CT-2A mouse astrocytoma model. ( 31082814 )
2019
17
Primary spinal pilocytic astrocytoma: clinical study with long-term follow-up in 16 patients and a literature review. ( 31098788 )
2019
18
Language Cerebro-cerebellar Reorganization in Children After Surgery of Right Cerebellar Astrocytoma: a fMRI Study. ( 31111430 )
2019
19
A systemic insight into astrocytoma biology across different grades. ( 30146735 )
2019
20
Expression and clinicopathological significance of Nck1 in human astrocytoma progression. ( 30146921 )
2019
21
Alternative lengthening of telomeres, ATRX loss and H3-K27M mutations in histologically defined pilocytic astrocytoma with anaplasia. ( 30192422 )
2019
22
Granular cell astrocytoma: an aggressive IDH-wildtype diffuse glioma with molecular genetic features of primary glioblastoma. ( 30222900 )
2019
23
Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma. ( 30251337 )
2019
24
IDH mutant astrocytoma: biomarkers for prognostic stratification and the next frontiers. ( 30326147 )
2019
25
Endoscopic transnasal resection of optic pathway pilocytic astrocytoma. ( 30338361 )
2019
26
Solid non-enhancing cerebellar pilocytic astrocytoma case report. ( 30366781 )
2019
27
Different behaviour of DVL1, DVL2, DVL3 in astrocytoma malignancy grades and their association to TCF1 and LEF1 upregulation. ( 30468298 )
2019
28
ATRX protein loss and deregulation of PI3K/AKT pathway is frequent in pilocytic astrocytoma with anaplastic features. ( 30499772 )
2019
29
Treatment of corneal neovascularization with topical aflibercept in a case of exposure keratopathy following cerebellar astrocytoma surgery. ( 30574927 )
2019
30
Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma. ( 30575814 )
2019
31
Supratentorial high-grade astrocytoma with leptomeningeal spread to the fourth ventricle: a lethal dissemination with dismal prognosis. ( 30604394 )
2019
32
Clinical characteristics, long-term complications and health-related quality of life (HRQoL) in children and young adults treated for low-grade astrocytoma in the posterior fossa in childhood. ( 30623287 )
2019
33
MR imaging features of spinal pilocytic astrocytoma. ( 30642288 )
2019
34
Astrocytoma progression scoring system based on the WHO 2016 criteria. ( 30643174 )
2019
35
Extent of resection predicts risk of progression in adult pilocytic astrocytoma. ( 30653383 )
2019
36
Oligo-astrocytoma in LZTR1-related Noonan syndrome. ( 30664951 )
2019
37
Importance of GFAP isoform-specific analyses in astrocytoma. ( 30667110 )
2019
38
Surgical Management and Outcome of a Bilateral Thalamic Pilocytic Astrocytoma: Case Report and Review of the Literature. ( 30677772 )
2019
39
Hemorrhagic presentation of frontal partially calcified pilocytic astrocytoma in an 18-year-old woman: A case report and literature review as "clinical case". ( 30711258 )
2019
40
Mechanisms of Toxicity of Industrially Relevant Silicomanganese Dust on Human 1321N1 Astrocytoma Cells: An In Vitro Study. ( 30744184 )
2019
41
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients. ( 30753611 )
2019
42
Atypical anaplastic astrocytoma with unique molecular features and diffuse leptomeningeal spread in a child with long-term survival. ( 30765449 )
2019
43
The benefit of surveillance imaging for paediatric cerebellar pilocytic astrocytoma. ( 30770993 )
2019
44
Unusual KRAS missense mutation (p.E63K) in patient with juvenile pilocytic astrocytoma of the tectum. ( 30798277 )
2019
45
The Expression of Leptin and Its Receptor During Tumorigenesis of Diffuse Gliomas such as Astrocytoma and Oligodendroglioma- Grade II, III and IV (NOS) ( 30803210 )
2019
46
Regorafenib in patients with recurrent high-grade astrocytoma. ( 30820715 )
2019
47
A systematic review of outcome in intramedullary ependymoma and astrocytoma. ( 30833131 )
2019
48
Comparable Genomic Copy Number Aberrations Differ across Astrocytoma Malignancy Grades. ( 30871102 )
2019
49
Proliferation-dominant high-grade astrocytoma: survival benefit associated with extensive resection of FLAIR abnormality region. ( 30901758 )
2019
50
Holocord Pilocytic Astrocytoma in an Adult: A Rare Case Report and Review of the Literature. ( 30902768 )
2019

Variations for Astrocytoma

ClinVar genetic disease variations for Astrocytoma:

6 (show all 41)
# Gene Variation Type Significance SNP ID Assembly Location
1 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
2 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406
3 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
4 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
5 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
6 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic rs121918465 GRCh38 Chromosome 12, 112450407: 112450407
7 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
8 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869
9 TP53 NM_000546.5(TP53): c.848G> A (p.Arg283His) single nucleotide variant Conflicting interpretations of pathogenicity rs371409680 GRCh37 Chromosome 17, 7577090: 7577090
10 TP53 NM_000546.5(TP53): c.848G> A (p.Arg283His) single nucleotide variant Conflicting interpretations of pathogenicity rs371409680 GRCh38 Chromosome 17, 7673772: 7673772
11 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh38 Chromosome 2, 208248388: 208248388
12 IDH1 NM_001282386.1(IDH1): c.395G> A (p.Arg132His) single nucleotide variant Pathogenic/Likely pathogenic rs121913500 GRCh37 Chromosome 2, 209113112: 209113112
13 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 GRCh37 Chromosome 8, 38274849: 38274849
14 FGFR1 NM_023110.2(FGFR1): c.1638C> A (p.Asn546Lys) single nucleotide variant Pathogenic rs779707422 GRCh38 Chromosome 8, 38417331: 38417331
15 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh37 Chromosome 8, 38272308: 38272308
16 FGFR1 NM_023110.2(FGFR1): c.1966A> G (p.Lys656Glu) single nucleotide variant Pathogenic/Likely pathogenic rs869320694 GRCh38 Chromosome 8, 38414790: 38414790
17 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
18 IDH1 NM_001282387.1(IDH1): c.394C> T (p.Arg132Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
19 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh37 Chromosome 2, 209113113: 209113113
20 IDH1 NM_001282387.1(IDH1): c.394C> A (p.Arg132Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121913499 GRCh38 Chromosome 2, 208248389: 208248389
21 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh37 Chromosome 8, 38272306: 38272306
22 FGFR1 NM_023110.2(FGFR1): c.1968G> C (p.Lys656Asn) single nucleotide variant Likely pathogenic rs1057519897 GRCh38 Chromosome 8, 38414788: 38414788
23 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 GRCh37 Chromosome 8, 38274851: 38274851
24 FGFR1 NM_023110.2(FGFR1): c.1636A> G (p.Asn546Asp) single nucleotide variant Likely pathogenic rs1057519898 GRCh38 Chromosome 8, 38417333: 38417333
25 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 GRCh37 Chromosome 8, 38275397: 38275397
26 FGFR1 NM_023110.2(FGFR1): c.1543A> G (p.Met515Val) single nucleotide variant Likely pathogenic rs1057519899 GRCh38 Chromosome 8, 38417879: 38417879
27 H3F3A NM_002107.4(H3F3A): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519903 GRCh37 Chromosome 1, 226252135: 226252135
28 H3F3A NM_002107.4(H3F3A): c.83A> T (p.Lys28Met) single nucleotide variant Likely pathogenic rs1057519903 GRCh38 Chromosome 1, 226064434: 226064434
29 ARID1A NM_006015.5(ARID1A): c.60_62dup (p.Pro21_Ser22insPro) duplication Conflicting interpretations of pathogenicity rs748085214 GRCh38 Chromosome 1, 26696463: 26696465
30 ARID1A NM_006015.5(ARID1A): c.60_62dup (p.Pro21_Ser22insPro) duplication Conflicting interpretations of pathogenicity rs748085214 GRCh37 Chromosome 1, 27022954: 27022956
31 ARID1B NM_020732.3(ARID1B): c.751T> G (p.Cys251Gly) single nucleotide variant Uncertain significance rs1276300860 GRCh37 Chromosome 6, 157099814: 157099814
32 ARID1B NM_020732.3(ARID1B): c.751T> G (p.Cys251Gly) single nucleotide variant Uncertain significance rs1276300860 GRCh38 Chromosome 6, 156778680: 156778680
33 EPHA5 NM_004439.7(EPHA5): c.1043A> G (p.Asp348Gly) single nucleotide variant Uncertain significance rs200932017 GRCh38 Chromosome 4, 65495411: 65495411
34 EPHA5 NM_004439.7(EPHA5): c.1043A> G (p.Asp348Gly) single nucleotide variant Uncertain significance rs200932017 GRCh37 Chromosome 4, 66361129: 66361129
35 KMT2D NM_003482.3(KMT2D): c.15876G> C (p.Glu5292Asp) single nucleotide variant Uncertain significance rs1365163460 GRCh37 Chromosome 12, 49418638: 49418638
36 KMT2D NM_003482.3(KMT2D): c.15876G> C (p.Glu5292Asp) single nucleotide variant Uncertain significance rs1365163460 GRCh38 Chromosome 12, 49024855: 49024855
37 NC_000014.9: g.38411139_38421941dup duplication Likely pathogenic GRCh38 Chromosome 14, 38411139: 38421941
38 TSC1 NM_000368.4(TSC1): c.359T> C (p.Leu120Pro) single nucleotide variant Uncertain significance rs1554820262 GRCh38 Chromosome 9, 132925591: 132925591
39 TSC1 NM_000368.4(TSC1): c.359T> C (p.Leu120Pro) single nucleotide variant Uncertain significance rs1554820262 GRCh37 Chromosome 9, 135800978: 135800978
40 PTPN11 NM_002834.4(PTPN11): c.940T> C (p.Phe314Leu) single nucleotide variant Uncertain significance GRCh38 Chromosome 12, 112477863: 112477863
41 PTPN11 NM_002834.4(PTPN11): c.940T> C (p.Phe314Leu) single nucleotide variant Uncertain significance GRCh37 Chromosome 12, 112915667: 112915667

Cosmic variations for Astrocytoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM10672 TP53 central nervous system,cerebrum,glioma,astrocytoma Grade II c.577C>T p.H193Y 17:7674954-7674954 0
2 COSM10656 TP53 central nervous system,cerebrum,glioma,astrocytoma Grade II c.742C>T p.R248W 17:7674221-7674221 0
3 COSM476 BRAF central nervous system,cerebrum,glioma,astrocytoma Grade II c.1799T>A p.V600E 7:140753336-140753336 0

Copy number variations for Astrocytoma from CNVD:

7 (show top 50) (show all 436)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13337 1 1 124300000 Loss Astrocytoma
2 13347 1 1 125000000 Deletion Astrocytoma
3 13376 1 1 2300000 Amplification AURKAIP1 Astrocytoma
4 13377 1 1 2300000 Amplification C1orf159 Astrocytoma
5 13378 1 1 2300000 Amplification CDC2L1 Astrocytoma
6 13379 1 1 2300000 Amplification CDC2L2 Astrocytoma
7 13380 1 1 2300000 Amplification CPSF3L Astrocytoma
8 13381 1 1 2300000 Amplification GNB1 Astrocytoma
9 13382 1 1 2300000 Amplification HES4 Astrocytoma
10 13383 1 1 2300000 Amplification ISG15 Astrocytoma
11 13386 1 1 2300000 Amplification MIB2 Astrocytoma
12 13387 1 1 2300000 Amplification MMP23A Astrocytoma
13 13388 1 1 2300000 Amplification NOC2L Astrocytoma
14 13389 1 1 2300000 Amplification PRKCZ Astrocytoma
15 13390 1 1 2300000 Amplification SDF4 Astrocytoma
16 13391 1 1 2300000 Amplification SLC35E2 Astrocytoma
17 13757 1 1 28000000 Deletion Astrocytoma
18 13760 1 1 28000000 Deletion Astrocytoma
19 16428 1 124300000 247249719 Gain Astrocytoma
20 16544 1 12700000 16200000 Deletion Astrocytoma
21 30468 1 243700000 249250621 Deletion AKT3 Astrocytoma
22 30469 1 243700000 249250621 Deletion SDCCAG8 Astrocytoma
23 30470 1 243700000 249250621 Deletion ZNF238 Astrocytoma
24 31970 1 32400000 34600000 Deletion Astrocytoma
25 32218 1 34600000 44100000 Deletion Astrocytoma
26 35014 1 59000000 68900000 Deletion Astrocytoma
27 36950 1 8384389 8404226 Deletion SLC45A1 Astrocytoma
28 46536 10 82000000 135374737 Loss Astrocytoma
29 48496 11 1 52900000 Loss Astrocytoma
30 67045 12 35400000 132349534 Loss Astrocytoma
31 67785 12 44600000 69800000 Gain Astrocytoma
32 75152 13 16000000 114142980 Loss Astrocytoma
33 89238 15 17000000 100338915 Gain Astrocytoma
34 97277 16 1 38200000 Loss Astrocytoma
35 97302 16 1 6300000 Amplification ABCA3 Astrocytoma
36 97303 16 1 6300000 Amplification AXIN1 Astrocytoma
37 97304 16 1 6300000 Amplification C1QTNF8 Astrocytoma
38 97305 16 1 6300000 Amplification CACNA1H Astrocytoma
39 97306 16 1 6300000 Amplification CREBBP Astrocytoma
40 97307 16 1 6300000 Amplification DNAJA3 Astrocytoma
41 97308 16 1 6300000 Amplification HMOX2 Astrocytoma
42 97309 16 1 6300000 Amplification IGFALS Astrocytoma
43 97310 16 1 6300000 Amplification MAGMAS Astrocytoma
44 97311 16 1 6300000 Amplification MAPK8IP3 Astrocytoma
45 97312 16 1 6300000 Amplification MMP25 Astrocytoma
46 97313 16 1 6300000 Amplification MPG Astrocytoma
47 97314 16 1 6300000 Amplification MRPL28 Astrocytoma
48 97315 16 1 6300000 Amplification MSLN Astrocytoma
49 97316 16 1 6300000 Amplification NME4 Astrocytoma
50 97317 16 1 6300000 Amplification NTHL1 Astrocytoma

Expression for Astrocytoma

Search GEO for disease gene expression data for Astrocytoma.

Pathways for Astrocytoma

GO Terms for Astrocytoma

Biological processes related to Astrocytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.13 FGFR1 MIR21 PTPN11
2 positive regulation of vascular endothelial cell proliferation GO:1905564 8.62 FGFR1 MIR21

Sources for Astrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....